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Objectives. This study compared the efficacy and safety of
atorvastatin, fluvastatin, lovastatin, and simvastatin in patients
with documented atherosclerosis treated to U.S. National Choles-
terol Education Program (NCEP) recommended low-density-
lipoprotein (LDL) cholesterol concentration (<2100 mg/dl [2.59
mmol/liter]).
Background. For patients with advanced atherosclerosis, NCEP
recommends lipid-lowering drug therapy if LDL cholesterol re-
mains >2130 mg/dl (3.36 mmol/liter).
Methods. A total of 318 men or women with documented
atherosclerosis and LDL cholesterol >2130 mg/dl (3.36 mmol/liter)
and <2250 mg/dl (6.5 mmol/liter), and triglycerides <2400 mg/dl
(4.5 mmol/liter) participated in this 54-week, multicenter, open-
label, randomized, parallel-group, active-controlled, treat-to-
target study. Patients were titrated at 12-week intervals until the
LDL cholesterol goal was reached. Number of patients reaching
target LDL cholesterol levels and dose to reach target were
evaluated.
Results. At the starting doses, atorvastatin 10 mg produced
significantly greater decreases (p < 0.05) in plasma LDL choles-
terol than the other treatments. Subsequently, the percentage of
patients reaching goal at the starting dose was 32% for atorvasta-
tin, 1% for fluvastatin, 10% for lovastatin and 22% for simvastatin.
Atorvastatin-treated patients required a lower median dose than
other treatments. Median doses at week 54 with the last available
visit carried forward were atorvastatin 20 mg/day, fluvastatin
40 mg/day 1 colestipol 20 g/day, lovastatin 80 mg/day, simvastatin
40 mg/day.
Conclusions. A significantly greater number (p < 0.05) of
patients with confirmed atherosclerosis treated with atorvastatin
reached the target LDL cholesterol concentration at the starting
dose than patients treated with fluvastatin or lovastatin, and
significantly fewer (p < 0.05) patients treated with atorvastatin
required combination therapy with colestipol to achieve target
LDL cholesterol concentrations than all other statins tested.
(J Am Coll Cardiol 1998;32:665–72)
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As many as 13.5 million people in the United States are
afflicted with coronary heart disease (CHD) (1). Subsequently,
it remains the leading cause of death in Western society and
results in a healthcare burden estimated by the American
Heart Association at $66.4 billion in the United States in 1996
(1,2). The role of serum cholesterol in the development of
atherosclerosis is well established (3). Clinical trials have
demonstrated that elevated serum low-density-lipoprotein
(LDL) cholesterol is associated with increased risk of CHD
and that lowering LDL cholesterol reduces morbidity and
mortality in patients with or without established cardiovascular
disease (4–7). In 1993, the Adult Treatment Panel Report of
the National Cholesterol Education Program (NCEP) outlined
an updated systematic clinical approach to treating high blood
cholesterol in adults (8). These NCEP guidelines are based on
the patient’s existing LDL cholesterol concentration and risk
for CHD. For those patients with advanced disease and
documented CHD or PVD, the expert panel recommends
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lipid-lowering drug treatment if, after an attempt at dietary
intervention, LDL cholesterol remains $130 mg/dl (3.36
mmol/liter) (8).
Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitor (reductase inhibitor) that has been
shown to lower LDL cholesterol levels from 41% to 60%
across the dose range in patients with primary hypercholester-
olemia (9–11). In this study of patients with documented
atherosclerosis, we prospectively evaluated the ability of ator-
vastatin to treat patients to their NCEP LDL cholesterol goal
compared to three of the most frequently prescribed agents
(fluvastatin, lovastatin and simvastatin), thereby providing the
first direct comparison of marketed reductase inhibitors in this
patient population.
Methods
Study design. This 54-week, open-label, randomized,
parallel-group, active-controlled, treat-to-target study in pa-
tients with documented atherosclerosis consisted of three
phases: an optional 8-week screening/dietary assessment
phase, a 4-week lead-in phase and a 54-week open-label
treatment phase (Fig. 1). Ten primary lipid centers in the
United States coordinated activities of 10 primary and 10
secondary care facilities (satellite centers) treating patients
with established atherosclerosis. Identical protocols were sub-
mitted to each center and reviewed and approved by an
appropriate institutional review board. Patients gave written
informed consent prior to participation. Before the lead-in
phase, men or women of nonchild-bearing potential with
documented atherosclerosis, aged 18 to 80 years, with a body
mass index not more than 32 kg/m2, were screened for
eligibility with a physical examination, medical history, clinical
laboratory evaluation, urinalysis and a lipid profile. Patients
taking a lipid-lowering drug could be considered for screening
after a 4-week washout period with the exception of probucol,
which must have been discontinued for at least 6 months.
Eligible patients were required to adhere to the NCEP Step I
or Step II diet or an equivalent lipid-restricted diet throughout
the study and to complete and return a 3-day diet diary at the
first visit of baseline (8,12). Lipid levels of patients beginning
dietary modification were allowed to stabilize over an 8-week
period before the patient entered the 4-week lead-in phase.
The 4-week lead-in phase was used to further evaluate the
patient’s eligibility and to establish baseline values for a
number of study parameters. Estimated mean LDL cholesterol
values of $130 mg/dl (3.36 mmol/liter) and #250 mg/dl
(6.5 mmol/liter) as calculated by the Friedewald formula were
necessary for inclusion in the study (13). Patients were ex-
cluded if they had hypersensitivities to reductase inhibitors or
bile acid sequestering resins; were taking any prohibited
medications; were pregnant or breast-feeding; had secondary
causes of hyperlipoproteinemia such as uncontrolled hypothy-
roidism, nephrotic syndrome, severe renal dysfunction or
uncontrolled diabetes mellitus Type I or II; had active liver
disease or hepatic dysfunction; had a myocardial infarction,
Abbreviations and Acronyms
ALT 5 alanine aminotransferase
AST 5 aspartate aminotransferase
CHD 5 coronary heart disease
FRR 5 Food Record Rating
HDL 5 high-density-lipoprotein
LDL 5 low-density-lipoprotein
NCEP 5 National Cholesterol Education Program
Figure 1. Study design. BID 5 administered twice daily; QD 5
administered once daily.
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coronary angioplasty, coronary artery bypass graft surgery
and/or severe or unstable angina pectoris within 1 month of
screening; had participated in another clinical study in which
study medication was received within 30 days of screening for
this study; and/or had significant abnormalities that the inves-
tigator judged could compromise the patient’s safety or suc-
cessful participation in the study. Patients could not take
lipid-regulating drugs not prescribed in the protocol, any
immunosuppressive agent and/or drugs known to be associated
with rhabdomyolysis in combination with reductase inhibitors.
Eligible patients were randomized to the starting dose of
atorvastatin 10 mg/day, fluvastatin 20 mg/day, lovastatin
20 mg/day or simvastatin 10 mg/day. During the 54-week
treatment phase, lipids were measured at 6- to 12-week
intervals, and dose titration occurred at 12-week intervals
(weeks 12, 24, 36 and/or 48). Dose titration was based on the
mean LDL cholesterol value of the two most recent measure-
ments. Investigators had the option of increasing the study
medication dose for patients whose mean LDL cholesterol was
either $100 mg/dl (2.59 mmol/liter) (NCEP guideline) or
$105 mg/dl (2.71 mmol/liter) (less stringent criterion). The
less stringent criterion allowed for common clinical practice
where an investigator may not wish to increase the dose of
medication to lower an LDL cholesterol value from 105 mg/dl
to 100 mg/dl. The doses of reductase inhibitors could be
increased to a maximum of 80 mg/day for atorvastatin,
40 mg/day for fluvastatin, 80 mg/day for lovastatin and
40 mg/day for simvastatin. If the target LDL cholesterol
concentration was not achieved at the maximum dose of
reductase inhibitor, colestipol was added to the patient’s
regimen, initially at 10 g (5 g twice daily). Based on the
patient’s response, colestipol dose could be increased after
another 12-week interval up to a maximum of 20 g/day. If the
patient could not tolerate colestipol, the dose could be de-
creased or totally withheld. Once the target LDL cholesterol
concentration was reached, the patient’s dose of mono- or
combination-therapy was maintained until the end of the study
with no further titrations allowed regardless of subsequent
LDL cholesterol values. At weeks 0 and 54, patients completed
a 24-hour dietary diary. Contents of the diary were reviewed by
the investigator for completeness and sent to the Chicago
Center for Clinical Research where a Food Record Rating
(FRR) score was calculated (14). Every effort within the
bounds of safety, patient choice and the provisions of informed
consent was made to enable patients to complete the study.
Patients received either atorvastatin, fluvastatin, lovastatin
or simvastatin based on a randomization code. With the
exception of atorvastatin, all study medications were supplied
in marketed medication containers. Compliance was assessed
at each clinic visit by inquiry and tablet count. The investigator
reported patients who took less than 80% of their prescribed
medication at each visit as noncompliant. Noncompliant pa-
tients were counseled regarding the importance of following
dosing instructions but were not dropped from the study.
Patients who were noncompliant because of intolerance to
colestipol were instructed to continue in the study at the
highest tolerated colestipol dose.
Efficacy and safety measurements. Clinical and safety eval-
uations and lipid profiles were managed through a central
laboratory (Pacific Biometrics Research Foundation, Seattle,
Washington) accredited by the College of American Patholo-
gists and standardized by the Centers for Disease Control.
Serum samples for lipid profiles were collected after a mini-
mum 12-h fast (water allowed). If the patient had not fasted,
the visit was rescheduled within 3 days. Study medication was
taken at approximately the same time of day and blood
samples for lipid profiles were drawn between 6 and 18 h
postdose. Patients were not to miss any study medication doses
within 48 h of a clinic visit; otherwise the visit was rescheduled.
LDL cholesterol, triglycerides, total cholesterol and high-
density-lipoprotein (HDL) cholesterol were evaluated at 6-
and 12-week intervals until patients reached NCEP goals, then
at 12-week intervals through the remainder of the study. Total
plasma cholesterol and triglyceride levels were determined
enzymatically with the Hitachi 737 analyzer (15). Plasma HDL
cholesterol was determined enzymatically after LDL- and
very-low-density-lipoprotein cholesterol were selectively re-
moved from the plasma sample by heparin and magnesium
chloride precipitation (16). LDL cholesterol was estimated by
the Friedewald formula (LDL cholesterol 5 total choles-
terol 2 [HDL cholesterol 1 (triglyceride 3 0.2)] for triglycer-
ide levels ,400 mg/dl (4.52 mmol/liter) (13). For triglycerides
$400 mg/dl, LDL cholesterol was determined by ultracentrif-
ugation (17). Apolipoprotein B was evaluated at 24 and 54
weeks and was determined by fixed-rate nephelometry (18).
A full clinical laboratory evaluation was determined at
screening, at randomization and at the end of the study, while
evaluations for safety (alanine aminotransferase, aspartate
aminotransferase and creatine phosphokinase) were done at
all intervening visits. Adverse events were recorded at each
clinic visit and up to 15 days after treatment stopped. Associ-
ated adverse events were those the investigator judged defi-
nitely, probably or possibly related to treatment as well as
those for which the investigator indicated an unknown rela-
tionship to treatment or insufficient available information for
evaluation.
Statistical analysis. Power. The sample size calculation
was based on a two-sided t-test at the 5% level of significance.
The percent of patients reaching target at each visit and the
mean number of visits needed to achieve target LDL choles-
terol levels were estimated. Based on these estimates, the
difference in the mean number of visits to reach target between
atorvastatin and simvastatin was 1.80. The estimated standard
deviation was 3.0. Using these parameters, a sample of 45
patients per group would detect a difference of 1.8 visits with
80% power. Estimating a 20% dropout rate yielded a treat-
ment group requirement of approximately 60 patients.
Efficacy. Descriptive statistics were prepared for all base-
line demographic and lipid variables. Statistical tests were
performed on all data from weeks 12 (starting doses), 24 (prior
to any colestipol combination therapy) and 54 (end of study).
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Efficacy analyses were performed on data from an intent-to-
treat population, defined as all patients randomized to treat-
ment and received at least 1 dose of study medication and who
had at least 1 lipid measurement taken after randomization.
For this population, the last available postrandomization lipid
measurement was carried forward to impute missing observa-
tions. All statistical tests were two-sided and conducted at the
5% level of significance. A comparison between treatment
groups of the percent change from baseline at weeks 12, 24 and
54 was carried out using analysis of covariance. The primary
model included treatment and center effects and the baseline
lipid value as a covariate. Treatment-by-center and treatment-
by-covariate interactions were evaluated. Dunnett’s test was
used to perform pairwise comparisons between atorvastatin
and each of the other three treatments.
For determining the number of patients reaching LDL
cholesterol goal, patients whose mean LDL cholesterol was
,105 mg/dl (2.7 mmol/liter) and whose study medication had
not been increased were considered responders. Patients were
counted as responders at week 54 if they had achieved
responder status at that visit or at any prior titration visit,
regardless of titration. All patients who withdrew before week
54 without having met responder criteria were counted as
nonresponders. To validate the use of 105 mg/dl as an alter-
native and reliable NCEP LDL cholesterol goal, a comparative
sensitivity analysis was performed on the number of patients
reaching LDL cholesterol goal using the accepted NCEP
criteria of 100 mg/dl (2.58 mmol/liter).
A comparison between treatment groups in responders by
week 54 of the study was carried out using a Cochran–Mantel–
Haenszel (CMH) analysis stratified by center. The colestipol
required by each treatment group to reach LDL-cholesterol
goal was compared by analysis of variance. A between-
treatment comparison of the time to reach target LDL choles-
terol values was carried out using the generalized Wilcoxon
test without stratification by center.
Safety. All patients who received study medication were
evaluated for safety. Adverse events and laboratory deviations
outside the normal range were recorded at clinic visits
throughout the study. Adverse events were summarized to
assess the adverse event rate for the treatment groups. An
increase in alanine aminotransferase (ALT) or aspartate ami-
notransferase (AST) levels greater than 3 times the upper limit
of normal and an increase in creatine kinase greater than 10
times upper limit of normal with muscle pain, tenderness or
weakness were considered clinically important laboratory de-
viations due to the increased incidence of these laboratory
events with reductase inhibitors.
Results
Demographics. A total of 318 patients with documented
atherosclerosis were randomized into the study with baseline
characteristics similar for all treatment groups (Table 1).
Overall, the majority of participants were men (68%), primar-
ily white (93%), with a mean age of 63 years (range 34 to 80
years). Mean baseline lipid values appeared similar across
treatment groups.
Compliance. In this study compliance, based on tablet
counts at each visit, was similar and high for all treatment
groups, ranging across visits from 92% to 100% in the atorva-
statin group, 83% to 97% in the fluvastatin group, 91% to 96%
in the lovastatin group and 88% to 99% in the simvastatin
group. FRR scores at baseline and the end of the study were
similar across treatments, suggesting that consistent dietary
practices were maintained throughout the study.
Disposition. Five patients lacked a postrandomization lipid
measurement and five patients were off study medication .3
Table 1. Baseline Patient Characteristics
Characteristic
Atorvastatin
(n 5 80)
Fluvastatin
(n 5 80)
Lovastatin
(n 5 81)
Simvastatin
(n 5 77)
All Patients
(n 5 318)
Sex (n, %)
Men 50 (63) 62 (78) 51 (63) 53 (69) 216 (68)
Women 30 (38) 18 (23) 30 (37) 24 (31) 102 (32)
Race (n, %)
White 75 (94) 74 (93) 74 (91) 73 (95) 296 (93)
Other 5 (6) 6 (7) 7 (8) 4 (5) 22 (7)
Age (yr)
Median 64 64 65 63 64
Range 34–79 44–77 35–80 34–79 34–80
Mean (SE) 62 (1.1) 62 (1.0) 64 (1.1) 63 (1.1) 63 (0.5)
Lipid values (mg/dl) (Mean [SE])
LDL-C 173 (4.0) 170 (3.1) 175 (3.3) 172 (3.4) 173 (1.7)
TC 254 (4.4) 250 (4.0) 258 (3.7) 252 (4.2) 254 (2.0)
Total TG 203 (8.7) 191 (7.0) 214 (9.3) 193 (7.8) 201 (4.1)
HDL-C 41 (1.2) 41 (1.2) 40 (1.2) 41 (1.4) 41 (0.6)
Total apoB 127 (2.1) 125 (1.9) 131 (2.0) 128 (2.2) 128 (1.0)
apoB 5 apolipoprotein B; HDL-C 5 high-density-lipoprotein cholesterol; LDL-C 5 low-density-lipoprotein cholesterol; SE 5 standard error; TC 5 total
cholesterol; TG 5 triglyceride.
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days before their only lipid measurement. Data for these
patients were not included in efficacy evaluations. Baseline
lipid values of patients with efficacy data were similar among
treatment groups and similar to those of the entire population.
For all treatment groups, the majority of nonresponders
completed the study.
Exposure. The greatest exposure to atorvastatin was at the
initial dose of 10 mg/day. In comparison, the greatest exposure
to the other reductase inhibitors occurred at the maximum
doses of 40 mg/day for fluvastatin, 80 mg/day for lovastatin,
and 40 mg/day for simvastatin. The greatest exposure to
reductase inhibitor plus colestipol combination therapy was
among patients randomized to fluvastatin. Median dose of
each treatment group at week 54 (with the last available
observation carried forward) was: atorvastatin, 20 mg/day;
fluvastatin, 40 mg/day plus colestipol 20 g/day; lovastatin,
80 mg/day; and simvastatin, 40 mg/day. The percentage of each
treatment group at initial dose, monotherapy with all other
doses and highest dose combined with colestipol for each
reductase inhibitor is shown in Figure 2. At the end of the
study, 36% of the atorvastatin patients were being treated at
the starting dose and only 8% required colestipol combination
therapy. In contrast, only 9% of fluvastatin patients were still at
the starting dose and 76% required combination therapy, 15%
of lovastatin patients were at the starting dose and 35%
required combination therapy and 22% of simvastatin patients
were still at the starting dose and 33% required combination
therapy.
Efficacy. At weeks 12 and 24 the mean percent decrease in
LDL cholesterol from baseline was greater among
atorvastatin-treated patients than among patients in other
treatment groups (Table 2). Statistical evaluation at week 12
data indicated that, at the starting dose, atorvastatin decreased
LDL cholesterol to a significantly greater degree than fluva-
statin, lovastatin or simvastatin (p , 0.05). At week 24, with
patients allowed one increase in dose, atorvastatin decreased
LDL cholesterol to a significantly greater degree than fluva-
statin or lovastatin (p , 0.05). Statistical evaluation of week 54
data, where patients may have received the full dosage range
plus colestipol combination therapy, indicated that atorvastatin
decreased LDL cholesterol from baseline to a significantly
greater degree than fluvastatin (p , 0.05).
NCEP goals. After 12 weeks of treatment, when all pa-
tients were at the starting dose of treatment, a significantly
greater percentage of the atorvastatin-treated patients (32%)
achieved the target LDL cholesterol goal compared to 1% for
fluvastatin- and 10% for lovastatin-treated patients, respec-
tively (p , 0.05), but not compared to 22% for simvastatin-
treated patients. A significantly greater percentage of
atorvastatin- (53%) than fluvastatin- (10%) or lovastatin-
treated patients (31%) reached target LDL cholesterol levels
by week 24 (p , 0.05), but not compared to 39% for
simvastatin-treated patients. A total of 223 patients met their
target LDL cholesterol goal by week 54. Response by week 54
was significantly better among atorvastatin-treated patients
(83%) compared to fluvastatin-treated patients (50%) (p ,
0.05). This response was not significantly better than in
Figure 2. Dose distribution by percentages of patients in each
treatment group at week 54 (with the last available observation
carried forward). Starting dose: 10 mg atorvastatin and simvastatin;
20 mg fluvastatin and lovastatin. All other monotherapy doses: 20 to
80 mg atorvastatin; 40 mg fluvastatin; 40 to 80 mg lovastatin; 20 to
40 mg simvastatin. Highest dose plus colestipol (up to 20 g/day): 80 mg
atorvastatin and lovastatin; 40 mg fluvastatin and simvastatin. White
portion 5 starting dose; gray portion 5 all other monotherapy doses;
black portion 5 highest dose of reductase inhibitors plus colestipol.
Table 2. Mean Percent Change† From Baseline in Lipid Parameters
Lipid Parameter
Atorvastatin
(n 5 78)
Fluvastatin
(n 5 76)
Lovastatin
(n 5 78)
Simvastatin
(n 5 76)
LDL-C
Week 12‡ 233 (1.3) 217* (1.3) 226* (1.3) 228* (1.3)
Week 24§ 236 (1.3) 221* (1.4) 230* (1.3) 233 (1.4)
Week 54\ 241 (1.6) 230* (1.6) 241 (1.6) 237 (1.6)
Total cholesterol
Week 12‡ 223 (1.0) 212* (1.0) 219* (1.0) 220 (1.0)
Week 24§ 226 (1.1) 215* (1.1) 223* (1.1) 224 (1.1)
Week 54\ 230 (1.2) 220* (1.3) 229 (1.2) 226 (1.2)
Triglycerides
Week 12‡ 211 (3.1) 26 (3.1) 26 (3.1) 211 (3.1)
Week 24§ 216 (2.9) 29 (2.9) 214 (2.9) 220 (2.9)
Week 54\ 219 (2.9) 22* (3.0) 214 (2.9) 215 (3.0)
HDL-C
Week 12‡ 9 (1.3) 5 (1.4) 6 (1.3) 9 (1.3)
Week 24§ 8 (1.5) 8 (1.5) 9 (1.5) 10 (1.5)
Week 54\ 7 (1.7) 7 (1.7) 12 (1.7) 11 (1.7)
apoB
Week 12‡ ND ND ND ND
Week 24§ 227 (1.2) 216* (1.3) 223* (1.2) 224* (1.2)
Week 54\ 229 (1.4) 221* (1.4) 227 (1.3) 225* (1.4)
NonHDL-C/HDL-C
Week 12‡ 234 (1.5) 219* (1.5) 226* (1.5) 231 (1.5)
Week 24§ 236 (1.6) 224 (1.6) 233 (1.6) 236 (1.6)
Week 54\ 240 (1.7) 229 (1.8) 241 (1.7) 239 (1.8)
apoB 5 apolipoprotein B; HDL-C 5 high-density-lipoprotein cholesterol;
LDL-C 5 low-density-lipoprotein cholesterol; ND 5 not determined. *Signifi-
cantly different from atorvastatin (p , 0.05). †Adjusted mean provided for
percent change based on analysis of covariance models. ‡These data represent
the use of drugs at the starting dose: atorvastatin 10 mg, fluvastatin 20 mg,
lovastatin 20 mg and simvastatin 10 mg. §These data represent the use of drugs
across dosage ranges: atorvastatin 10 to 20 mg, fluvastatin 20 to 40 mg, lovastatin
20 to 40 mg and simvastatin 10 to 20 mg. \These data represent the use of drugs
across the full dosage range and in combination with colestipol.
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lovastatin- (81%) or simvastatin-patients (75%) treated; how-
ever, the amount of colestipol needed to achieve LDL choles-
terol goals was significantly greater in the lovastatin and
simvastatin groups than in the atorvastatin group (p , 0.05). A
post hoc analysis looked at the percentage of patients who
attained their NCEP target LDL cholesterol concentration on
reductase inhibitor alone (monotherapy). Seventy-nine per-
cent of atorvastatin patients met goal compared to 11% on
fluvastatin, 56% on lovastatin and 59% on simvastatin (p ,
0.05).
Atorvastatin-treated patients had a median response time
of 170 days compared to 344 days for fluvastatin-, 253 for
lovastatin- and 253 for simvastatin-treated patients, from life-
table analyses (p , 0.05). Cumulative response over time is
shown in Figure 3. Of the 223 patients who met an LDL
cholesterol goal of 105 mg/dl (2.71 mmol/liter), 204 also met
the stricter criteria of 100 mg/dl (2.58 mmol/liter). Those
patients whom the investigators chose not to titrate up in dose
were evenly distributed across treatment groups. The sensitiv-
ity analysis which considered the strict goal of 100 mg/dl (2.58
mmol/liter) showed similar results to the data at 105 mg/dl
(2.71 mmol/liter), where 78% of atorvastatin-treated patients
at week 54 reached goal versus 42% fluvastatin-, 74%
lovastatin- and 70% simvastatin-treated patients.
Safety. Adverse events. At week 54, atorvastatin showed a
safety profile similar to that of the other reductase inhibitors.
Adverse events occurring on combination therapy at week 54
were summarized as treatment-related when judged related to
either reductase inhibitor or colestipol treatment or both.
Patients in the fluvastatin treatment group had about a twofold
higher overall incidence of treatment-related adverse events
than patients in the other treatment groups. This higher
percentage in the fluvastatin group was due primarily to a
higher incidence of digestive system symptoms, particularly
constipation and flatulence, which are often associated with
colestipol treatment (Table 3). Approximately 76% of patients
in the fluvastatin group were receiving add-on colestipol
therapy. With this exception, no notable treatment differences
were observed when adverse events were stratified by age,
gender or race. Related adverse events that occurred in at least
two atorvastatin-treated patients were constipation, headache,
dizziness, arthralgia and rash. Within a body system other than
digestive, the number (1 to 4) and percentage (1% to 5%) of
patients with a specific type of event were too low to make
clinically meaningful comparisons between treatment groups.
Serious adverse events were most often related to the
cardiovascular system, with angina pectoris and myocardial
infarction the most frequent events. With the exception of one
lovastatin-treated patient (pancreatitis), none of these events
was considered related to treatment.
Eleven patients withdrew because of treatment-related
adverse events, with the overall incidence of events similar
between treatment groups (three patients withdrew in the
atorvastatin group, four in the fluvastatin group, two in the
lovastatin group and two in the simvastatin group). One
atorvastatin-, one fluvastatin- and two simvastatin-treated pa-
tients died. None of these deaths was considered related to
treatment.
Laboratory parameters. Minor and sporadic elevations in
ALT and AST were noted in all treatment groups. One
fluvastatin patient had persistent alanine transaminase levels
.3 times the upper limit of normal, and another fluvastatin
patient had persistent aspartate transaminase elevations .3
times the upper limit of normal. There were no clinically
Figure 3. Cumulative percentage of patients reaching the NCEP-
recommended LDL cholesterol goal (#100 mg/dl). The median dose
for each treatment group at week 54 (with the last available observa-
tion carried forward) was atorvastatin 20 mg/day, fluvastatin 40 mg/day
plus colestipol 20 g/day, lovastatin 80 mg/day and simvastatin
40 mg/day.
Table 3. Week 54: Related† Adverse Events Experienced by at
Least 3% of Patients in Any Randomized Treatment Group‡
(Number [%] of Patients)
Body System
Adverse Event
Atorvastatin
(n 5 80)
Fluvastatin
(n 5 80)
Lovastatin
(n 5 81)
Simvastatin
(n 5 77)
Digestive 5 (6) 23 (29) 12 (15) 9 (12)
Constipation 2 (3) 7 (9) 6 (7) 5 (6)
Flatulence 0 (0) 8 (10) 3 (4) 2 (3)
Nausea 1 (1) 4 (5) 0 (0) 0 (0)
Diarrhea 1 (1) 3 (4) 0 (0) 0 (0)
Dyspepsia 0 (0) 2 (3) 2 (2) 2 (3)
Body as a whole 5 (6) 6 (8) 2 (2) 2 (3)
Headache 2 (3) 0 (0) 0 (0) 4 (5)
Asthenia 1 (1) 3 (4) 0 (0) 2 (3)
Abdominal Pain 0 (0) 2 (3) 2 (2) 2 (3)
Pain 0 (0) 2 (3) 0 (0) 0 (0)
Nervous system 3 (4) 1 (1) 1 (1) 1 (1)
Dizziness 2 (3) 0 (0) 0 (0) 1 (1)
Musculoskeletal 2 (3) 3 (4) 1 (1) 3 (4)
Arthralgia 2 (3) 0 (0) 1 (1) 1 (1)
Skin and appendages 2 (3) 3 (4) 2 (2) 2 (3)
Rash 2 (3) 2 (3) 1 (1) 2 (3)
Any Event 15 (19) 33 (41) 16 (20) 18 (23)
†Definitely, probably or possibly related to study medication. ‡Includes patients
on monotherapy and those on reductase inhibitor plus colestipol therapy.
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important changes in liver transaminase levels in any other
group. The proportion of patients with glucose elevations was
similar across treatment groups. For all patients this abnor-
mality was transient and not clinically meaningful. There were
no clinically important creatine kinase levels in any treatment
group. Changes in remaining parameters were not clinically
meaningful and showed no treatment-associated trends.
Discussion
This treat-to-target study provides a first-time, prospective,
direct comparison of lipid lowering in patients with established
atherosclerosis treated to their NCEP-recommended plasma
LDL cholesterol goal among four marketed reductase inhibi-
tors: atorvastatin, fluvastatin, lovastatin and simvastatin.
Efficacy. At week 12, the time point at which all patients
were receiving a starting dose of reductase inhibitor, atorva-
statin decreased LDL cholesterol significantly more than the
other compounds tested (p , 0.05). The week 54 time point
provided a 1-year look at treatment with patients on a variety
of doses and combination treatments. Baseline characteristics
between treatment groups were similar and all patients were
treated to the same LDL cholesterol goal. Median doses at
week 54 with the last available visit carried forward were
atorvastatin 20 mg/day, fluvastatin 40 mg/day 1 colestipol
20 g/day, lovastatin 80 mg/day and simvastatin 40 mg/day. At
week 54, atorvastatin decreased LDL cholesterol to a greater
extent than the other reductase inhibitors with statistical
significance (p , 0.05) compared to fluvastatin.
NCEP goals. In this study atorvastatin’s significant lipid-
lowering activity enabled more patients with established ath-
erosclerosis to reach the NCEP-recommended LDL choles-
terol concentration at the starting dose than patients treated
with fluvastatin or lovastatin (p , 0.05). Thirty-two percent of
the atorvastatin-treated patients achieved their target LDL
cholesterol concentration compared to 1% for fluvastatin-,
10% for lovastatin- and 22% for simvastatin-treated patients.
Only 8% of atorvastatin patients required colestipol combina-
tion therapy to achieve goal, compared to 76% of fluvastatin-,
35% of lovastatin- and 33% of simvastatin patients. In fact, the
slightly higher compliance rate for patients treated with ator-
vastatin may be a reflection of these patients reaching their
LDL cholesterol goal quickly and with a low rate of colestipol
combination therapy. The largest obstacle to adjuvant therapy
may be reduced compliance due to the occurrence of adverse
effects. A retrospective cohort study in patients with cardio-
vascular disease has reported that in patients treated with
niacin and/or colestipol, the cumulative drug discontinuance
rate for these agents was over 50% (19).
It can be argued that the type of patients recruited for this
study favored atorvastatin in respect to their starting LDL
cholesterol levels (170 to 175 mg/dl) and the level of reduction
required by most patients to reach their NCEP goal (approx-
imately 40%). It is important to note, however, that patients
had to have a starting LDL cholesterol level of $130 mg/dl to
enter the study. The patient population recruited for this study
is representative of the general patient population for which
lipid-lowering therapy would be prescribed.
Although the majority of analyses were performed on
patients achieving a slightly less stringent goal (105 mg/dl [2.71
mmol/liter]) than that outlined in NCEP guidelines (100 mg/dl
[2.58 mmol/liter]), the results of the analyses were unaffected
by this variation. We believe that the results at 105 mg/dl
provide a realistic interpretation of the data whereby most
physicians would not increase a patient’s dose of medication to
lower their LDL cholesterol from 105 to below 100 mg/dl (2.71
to 2.58 mmol/liter).
Conclusions. Medical practice guidelines are expanding in
use as the economic and clinical demands on medical practice
increase. Considering the well-established relationship be-
tween LDL cholesterol and atherosclerotic disease, the use of
NCEP guidelines is a logical and reasonable approach for the
treatment of hypercholesterolemia and ultimately CHD. Sev-
eral studies are currently ongoing to examine the effect of
atorvastatin on cardiovascular events. This study demonstrates
that more patients with established atherosclerosis reached
NCEP-recommended target LDL cholesterol concentration at
the starting dose (p , 0.05) with atorvastatin than with
fluvastatin or lovastatin and with less colestipol combination
therapy (p , 0.05) than fluvastatin, lovastatin or simvastatin.
Atorvastatin is a highly effective treatment for lowering LDL
cholesterol to NCEP guidelines.
The authors wish to thank and acknowledge the other participating investigators:
Paul Adballah, MD, Minor and James Medical, Seattle, WA; Charles Boyajian,
MD, Elk Grove Village, IL; Stephen Clark, MD, Jacksonville, FL; Michael
Crouch, MD, Family Practice Center, Houston, TX; Michael Davidson, MD,
Chicago Center for Clinical Research, Chicago, IL; Margaret Drehobl, MD,
Center for Health Care Medical Associates, San Diego, CA; Carlos Dujovne,
MD, University of Kansas Medical Center, Wichita, KS; James Early, MD,
Prevention Health Center, Wichita, KS; Keith Holten, MD, Providence/UC
Family Center, Cincinnati, OH; Kevin Holthaus, MD, Point Vedra Beach, FL;
Donald Hunninghake, MD, University of Minnesota, Minneapolis, MN; William
Insull, Jr., MD, Lipid Research Clinic, Houston, TX; Edward Langston, MD,
Family Practice Center, Houston, TX; Charles Margolis, MD, University of
Wyoming Family Practice Center, Cincinnati, OH; James McKenney, MD,
National Clinical Research, Richmond, VA; Helmut Schrott, MD, University of
Iowa, IA; Krishna Sikaria, MD, The Heart Center, St. Augustine, FL; Dennis
Sprecher, MD, University of Cincinnati Medical Center, Cincinnati, OH; and
Dance Trence, MD, Group Health of Fairview Riverside, Minneapolis, MN. The
authors also thank Perry Tresh for study management, Rachel E. Laskey for
assistance with the manuscript, as well as Dean Smith for his analytical expertise
and Pacific Biometrics Research Foundation and the Chicago Center for Clinical
Research.
References
1. American Heart Association. Heart and Stroke Facts: 1996 Statistical
Supplement. Dallas, TX, 1995.
2. Montague TJ, Tsuyuki RT, Burton JR, Dzavik V, Williams R, Teo KK.
Prevention and regressions of coronary atherosclerosis. Is it safe and
efficacious therapy? Chest 1994;105:718–26.
3. Gotto AM Jr, LaRosa CJ, Hunninghake D, et al. The cholesterol facts. A
summary of the evidence relating dietary fats, serum cholesterol, and
coronary heart disease. Circulation 1990;81:1721–33.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary
events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med 1996;335:1001–9.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of
671JACC Vol. 32, No. 3 BROWN ET AL.
September 1998:665–72 TREATING CHD PATIENTS TO US NCEP LDL CHOLESTEROL GOALS
cholesterol-lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383–9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:
1301–7.
7. Furberg CD, Adams HP Jr, Applegate WB, et al. Effects of lovastatin on
early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:
1679–87.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Summary of the Second Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection, Eval-
uation, and Treatment of High Blood Cholesterol in Adults (Adult Treat-
ment Panel II). JAMA 1993;269(23):3015–23.
9. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol
by 25% to 60% in patients with primary hypercholesterolemia by atorvasta-
tin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol
1995;15:678–82.
10. Davidson MM, McKenney JM, Stein EA, et al. Long-term efficacy and safety
of atorvastatin compared to lovastatin in hypercholesterolemic patients.
Am J Cardiol 1997;79:1475–81.
11. Bertolini S, Bon GB, Campbell LM, et al. The efficacy and safety of
atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Atherosclerosis 1997;130:191–7.
12. Remmell PS, Gorder DD, Hall Y, Tillotson JL. Assessing dietary adherence
in the Multiple Risk Factor Intervention Trial (MRFIT), I: Use of a dietary
monitoring tool. JAMA 1980;76:351–6.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration
of low density lipoprotein cholesterol in plasma without the use of a
centrifuge. Clin Chem 1972;22:98–101.
14. Feskanich D, Buzzard IM, Welch BT, et al. Comparison of a computerized
and manual method of food coding for nutrient intake studies. J Am Diet
Assoc 1988;88:1263–7.
15. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micro-
methods for plasma cholesterol, triglyceride and HDL-cholesterol with the
Lipid Clinics methodology. J Clin Chem Clin Biochem 1981;19:850.
16. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin man-
ganese precipitation procedure for estimating high density lipoprotein
cholesterol. J Lipid Res 1978;19:67–76.
17. Lipid and lipoprotein analysis: In: Manual of Laboratory Operations: LRC
Program Report (NIH) 75-628. US Department of Health, Education and
Welfare, 1974, Vol 1.
18. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical
Chemistry Standardization Project for measurement of apolipoproteins A-1
and B-II: evaluation and selection of candidate reference materials. Clin
Chem 1992;38:658–62.
19. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients
with cardiovascular disease: factors limiting achievement of lipid goals. Am J
Med 1996;100:197–204.
672 BROWN ET AL. JACC Vol. 32, No. 3
TREATING CHD PATIENTS TO US NCEP LDL CHOLESTEROL GOALS September 1998:665–72
